Insulin Delivery Devices Market Outlook Signals Expansion To $28.02 Billion Through 2030

The insulin delivery devices market is set to experience significant growth over the coming years, driven by evolving healthcare needs and technological advancements. This sector is increasingly critical as more individuals worldwide manage diabetes with better and more convenient delivery systems. Let's explore the current market outlook, key players, prominent trends, and segmentation details shaping the future of insulin delivery devices.

Projected Expansion of the Insulin Delivery Devices Market Size Until 2030
The market for insulin delivery devices is anticipated to expand strongly, reaching a valuation of $28.03 billion by 2030. This growth corresponds to a compound annual growth rate (CAGR) of 8.0% during the forecast period. Rising diabetes prevalence globally, increasing demand for simplified insulin administration, and growing emphasis on sustained diabetes care are some of the primary factors driving this expansion. Additionally, improved access to diabetes management in emerging economies, a surge in home healthcare adoption, and the introduction of more convenient delivery formats support this upward trend. Notable market patterns include a shift towards insulin pens over conventional syringes, heightened interest in insulin pumps for continuous delivery, a preference for portable and user-friendly devices, growth in home-based diabetes management solutions, and the rising popularity of disposable and pre-filled insulin delivery options.

Download a free sample of the insulin delivery devices market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18642&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Top Companies Leading the Insulin Delivery Devices Industry
Several prominent corporations hold strong positions in this competitive market, including Novo Nordisk A/S, Medtronic Plc, Insulet Corporation, Tandem Diabetes Care Inc., Ypsomed Holding AG, Becton dic*kinson and Company, Sanofi SA, Eli Lilly and Company, Abbott Laboratories, EOFlow Co. Ltd., Beta Bionics Inc., Bigfoot Biomedical Inc., CeQur Corporation, Emperra GmbH, Debiotech SA, AMF Medical SA, Aerami Therapeutics Inc., Andain Inc., Apex Medical Devices, and Animas Corporation.
In a notable development in September 2023, US-based Abbott acquired Bigfoot Biomedical, a manufacturer of insulin delivery devices, for an undisclosed sum. This acquisition strengthens Abbott's presence in diabetes care by enhancing its FreeStyle Libre continuous glucose monitoring portfolio. Abbott's strategy focuses on advancing connected health solutions that personalize and improve diabetes management outcomes.

Current Innovations and Emerging Trends in Insulin Delivery Devices
Innovative insulin pumps are at the forefront of development efforts within the market, offering continuous and customizable insulin delivery that adapts to individual needs. These programmable devices administer insulin through a catheter under the skin, providing a more precise diabetes management option compared to traditional methods. For example, Beta Bionics, a US-based medical technology firm, received FDA approval in May 2023 for its iLet ACE Pump and the iLet Dosing Decision Software. Designed for users aged six and up with type 1 diabetes, the iLet Bionic Pancreas combines two devices with an FDA-cleared integrated continuous glucose monitor (iCGM). It features an adaptive closed-loop algorithm that automatically manages insulin dosing based only on the user's body weight during initial setup, eliminating the need for manual adjustments. Additionally, the system simplifies mealtime insulin dosing by allowing users to classify meals as small, medium, or large, with the technology learning and adapting to individual insulin requirements over time.

View the full insulin delivery devices market report:
https://www.thebusinessresearchcompany.com/report/insulin-delivery-devices-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Segmentation Overview of the Insulin Delivery Devices Market
The insulin delivery devices market is categorized into several segments to provide a detailed understanding of market dynamics. These segments include:
1) By Type: Insulin Syringes, Insulin Jet Injectors, Pen Needles, Reusable Insulin Pens, Disposable Insulin Pens
2) By Disease Indication: Type 1 Diabetes, Type 2 Diabetes
3) By Distribution Channels: Hospital Pharmacies, Retail Pharmacies, Online Sales, Diabetes Clinics or Centers

Further subsegments break down each major category:
- Insulin Syringes are divided into Standard Syringes and Syringes with Fixed or Adjustable Needle Lengths.
- Insulin Jet Injectors include Needle-Free and High-Pressure variants.
- Pen Needles come in Short and Long versions.
- Reusable Insulin Pens are either pens with replaceable cartridges or refillable types.
- Disposable Insulin Pens consist of Single-Use and Pre-Filled pens.

This granular segmentation helps highlight the diversity of products available and the various channels through which patients access insulin delivery solutions worldwide.

New additions to our 2026 reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.